- Home
- SNX vs LEGN Comparison
SNX vs LEGN Comparison
Compare SNX & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNX | LEGN |
|---|---|---|
| Founded | 1980 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 5.9B |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SNX | LEGN |
|---|---|---|
| Price | $152.76 | $18.16 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | ★ $168.60 | $63.08 |
| AVG Volume (30 Days) | 397.2K | ★ 1.5M |
| Earning Date | 03-31-2026 | 03-10-2026 |
| Dividend Yield | ★ 1.25% | N/A |
| EPS Growth | ★ 25.16 | N/A |
| EPS | ★ 9.95 | N/A |
| Revenue | ★ $20,053,764,000.00 | N/A |
| Revenue This Year | $5.01 | $46.27 |
| Revenue Next Year | $4.18 | $28.77 |
| P/E Ratio | $15.34 | ★ N/A |
| Revenue Growth | ★ 17.65 | N/A |
| 52 Week Low | $92.23 | $16.24 |
| 52 Week High | $175.56 | $45.30 |
Technical Indicators
Market Signals| Indicator | SNX | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 41.03 | 44.37 |
| Support Level | $152.38 | $17.46 |
| Resistance Level | $159.61 | $20.39 |
| Average True Range (ATR) | 4.10 | 0.73 |
| MACD | -0.55 | 0.03 |
| Stochastic Oscillator | 12.94 | 23.89 |
Price Performance
Historical ComparisonAbout SNX TD SYNNEX Corporation
TD Synnex Corp is a distributor and solutions aggregator for the IT ecosystem. The company aggregates and distributes IT hardware, software, and systems including personal computing devices and peripherals, mobile phones and accessories, printers, server and data center infrastructure, hybrid cloud, security, networking, communications and storage solutions, and system components. Its geographical segments include the Americas, Europe, and APJ.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.